| William Larkin, | |
|
800 Scott And White Dr, College Station, TX 77845-6440 | |
| (979) 207-4000 | |
| (979) 207-4562 |
| Full Name | William Larkin |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 18 Years |
| Location | 800 Scott And White Dr, College Station, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760630065 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | N8807 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center- College Stati | College station, TX | Hospital |
| Baylor Scott & White Pavilion - Temple | Temple, TX | Hospital |
| St Joseph Regional Health Center | Bryan, TX | Hospital |
| Baylor Scott & White Medical Center - Round Rock | Round rock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scott And White Clinic | 8123923604 | 2131 |
News Archive
"China could be considering relaxing its ... one-child policy," which "is increasingly being seen as an impediment to growth and the harbinger of social problems," such as a declining workforce, Reuters reports.
China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.
Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. and the Translational Genomics Research Institute.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 4 days ago
| Entity Name | Scott & White Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093779704 PECOS PAC ID: 8123923604 Enrollment ID: O20031223000640 |
News Archive
"China could be considering relaxing its ... one-child policy," which "is increasingly being seen as an impediment to growth and the harbinger of social problems," such as a declining workforce, Reuters reports.
China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.
Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. and the Translational Genomics Research Institute.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Larkin, Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-2111 | William Larkin, 800 Scott And White Dr, College Station, TX 77845-6440 Ph: (979) 207-4000 |
News Archive
"China could be considering relaxing its ... one-child policy," which "is increasingly being seen as an impediment to growth and the harbinger of social problems," such as a declining workforce, Reuters reports.
China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, today announced the pricing of a follow-on offering of 1,550,000 shares of common stock at a public offering price of $38.00 per share.
Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. and the Translational Genomics Research Institute.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
› Verified 4 days ago
Dr. Tami Neal Fink, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 | |
Dr. Mark Sultenfuss, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 Fax: 979-207-2161 | |
Coley Gatlin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 830-431-1380 | |
Ben L Sueoka, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 | |
Yadvindera S Bains, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 800 Scott And White Dr, College Station, TX 77845 Phone: 979-207-4000 Fax: 979-207-4562 | |
Christopher Charles Bathurst, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 254-724-2111 | |
Christopher Prause, Radiology Medicare: Accepting Medicare Assignments Practice Location: 700 Scott And White Dr, College Station, TX 77845 Phone: 979-207-0100 |